Skip to main content

Market Overview

GSK Kick Starts Late-Stage Study With Medicago-Partnered COVID-19 Vaccine

Share:

GlaxoSmithKline Plc (NYSE: GSK) hopes for better luck with its second partner Medicago, after tripping up in a recent COVID-19 vaccine test with Sanofi SA (NASDAQ: SNY). 

  • GSK and Medicago will start Phase 3 testing of Medicago’s COVID-19 vaccine candidate combined with GSK’s pandemic adjuvant.
  • The companies penned a vaccine deal last year to test Medicago’s plant-derived recombinant coronavirus-like particles (CoVLPs) with GSK’s pandemic adjuvant system that has been used in previous epidemics.
  • A similar vaccine approach didn’t initially work out very well for Sanofi and GlaxoSmithKline, which posted weak results in older patients.
  • Last month, the companies corrected the vaccine’s formulation, GSK and Sanofi began a Phase 2 clinical trial of a new version of the vaccine.
  • Phase 3 with Medicago will be conducted in about 30,000 patients while also assessing the shot “to address emerging variants” in a feasibility test.
  • As part of the program, patients in the trial will get two doses of 3.75 micrograms of CoVLPs administered 21 days apart.
  • The trial is part of the ongoing phase 2/3 study that started last November.
  • The Phase 2 part of the trial should see early data out next month.
  • GSK, along with Vir Biotechnology Inc’s (NASDAQ: VIR), is evaluating a COVID-19 antibody therapy. Interim analysis of data from 583 patients demonstrated an 85% reduction in hospitalization or death.
  • Last week, Sanofi and Translate Bio began a trial of the mRNA Covid-19 vaccine.
  • Price Action: SNY and GSK shares are trading 0.8% and 0.78% higher at $49.11 and $36.16, respectively, in the market trading hours on the last check Tuesday.
 

Related Articles (GSK + TBIO)

View Comments and Join the Discussion!

Posted-In: COVID-19 Vaccine Phase 3 StudyBiotech News Health Care Contracts FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com